Skip to main content
SpringerLink
Log in

Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment

  • Systematic Review
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Background

The challenges of comparative effectiveness to support health technology assessment (HTA) agencies are important considerations in the choices of antipsychotic medications for the treatment of schizophrenia.

Objectives

Our aim was to assess the study methods used and outcomes reported in the published literature to address the question of comparative effectiveness of newer antipsychotic agents and the adequacy and availability of evidence to support HTA agencies.

Data Source

A systematic search of the PubMed database from 1 January 2009 to 30 September 2013 was conducted to identify studies evaluating new atypical antipsychotics reporting on comparative effectiveness.

Study Selection

The systematic review comprised of studies on schizophrenia patients where at least two drugs were being compared and at least one treatment group received one of the following second-generation antipsychotics: risperidone, olanzapine, aripiprazole, paliperidone, asenapine, iloperidone, lurasidone, and quetiapine. The included studies were also required to have an efficacy, safety or economic outcome, such as Positive and Negative Syndrome Scale (PANSS) score, weight gain, resource utilization, or costs.

Study Appraisal and Synthesis Methods

Two reviewers (BW and GK) independently applied the inclusion criteria. Disagreements between reviewers were resolved by consensus, referring to the original sources. Information on the methodology and outcomes was collected for each included study. This included study description, head-to-head drug comparison, patient population, study methodology, statistical methods, reported outcomes, study support, and journal type.

Results

A total of 198 studies were identified from electronic search methods. The largest category of studies was randomized controlled trials [RCTs] (N = 73; 36.9 %), which were largely directed at the regulatory endpoint. Fewer studies were undertaken for HTA-purposes cohort studies (N = 53; 26.8 %), meta-analyses (N = 32; 16.2 %), economic studies (N = 14; 7.1 %), and cross-sectional studies (N = 13; 6.6 %). Direct head-to-head comparisons preferred by HTA were dominated by the comparison involving olanzapine and risperidone, representing 149 (75.3 %) and 119 (60.1 %) studies, respectively. RCTs, which are the primary study type for regulatory submissions, showed a lack of bias. Studies aimed at HTA were not as well performed. Cohort studies suffered from bias in the selection of comparison groups, lack of control for confounders, and differential dropout rates. As a group, cross-sectional studies scored poorly for bias, with a primary failure to identify a representative sample. Economic studies showed highly variable bias, with bias in the representation of effectiveness data, model assumptions without validation, and lack of sensitivity analyses.

Limitations

One limitation of this systematic review is that it only included studies from 2009 to 2013, potentially excluding some earlier comparator studies, particularly those involving first-generation antipsychotics.

Conclusions

This review of comparative effectiveness studies of second-generation antipsychotic agents for schizophrenic patients revealed a wide range of study types, study methodologies, and outcomes. For traditional efficacy outcomes and select safety outcomes, there is strong evidence from many well-conducted studies; however, there are fewer studies of types preferred by HTA with limited head-to-head comparisons and a higher risk of bias in the execution of these studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Berger ML, Dreyer N, Anderson F, et al. Prospective observational studies to assess comparative effectiveness: the ISPOR Good Research Practices Task Force Report. Value Health. 2012;15:217–30.

    Article  PubMed  Google Scholar 

  2. European Medicines Agency. Guidance for the format and content of the protocol of non-interventional post authorisation safety studies. Available at: EMA/623947/2012http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/10/WC500133174.pdf. Accessed 23 Oct 2013.

  3. Hickam D, Totten A, Berg A, Rader K, Goodman S, Newhouse R, editors. The PCORI Methodology Report. 2013. Available at: http://www.pcori.org/assets/2013/11/PCORI-Methodology-Report.pdf. Accessed 07 Oct 2013.

  4. Davis JM, Janicak PG, Singla A, Sharma RP. Maintenance antipsychodc medication. In: Barnes TRE, editor. Antipsychotic drugs and their side-effects. New York: Academic Press; 1993.

    Google Scholar 

  5. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Yu IT, Tse SL. Workshop 11-sources of bias in studies of systematic reviews with or without meta-analysis. Hong Kong Med J. 2013;19(2):156–8.

    PubMed  Google Scholar 

  7. Drummond M, Sculpher M. Common methodological flaws in economic evaluations. Med Care. 2005;43(7 Suppl):5–14.

    PubMed  Google Scholar 

  8. Addington DE, Labelle A, Kulkarni J, Johnson G, Loebel A, Mandel FS. A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study. Can J Psychiatry. 2009;54(1):46–54.

    PubMed  Google Scholar 

  9. Alptekin K, Hafez J, Brook S, Akkaya C, Tzebelikos E, Ucok A, et al. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study. Int Clin Psychopharmacol. 2009;24(5):229–38.

    Article  PubMed  Google Scholar 

  10. Boter H, Peuskens J, Libiger J, Fleischhacker WW, Davidson M, Galderisi S, et al. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res. 2009;115(2–3):97–103.

    Article  PubMed  Google Scholar 

  11. Byerly MJ, Marcus RN, Tran QV, Eudicone JM, Whitehead R, Baker RA. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res. 2009;107(2–3):218–22.

    Article  PubMed  Google Scholar 

  12. Canuso CM, Dirks B, Carothers J, Kosik-Gonzalez C, Bossie CA, Zhu Y, et al. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry. 2009;166(6):691–701.

    Article  PubMed  Google Scholar 

  13. Castle DJ, Udristoiu T, Kim CY, Sarosi A, Pidrman V, Omar AN, et al. Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation. World J Biol Psychiatry. 2009;10(1):43–53.

    Article  PubMed  Google Scholar 

  14. de Oliveira IR, Elkis H, Gattaz WF, Chaves A, de Sena EP, de Matos ESFG, et al. Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol. CNS Spectr. 2009;14(2):93–102.

    PubMed  Google Scholar 

  15. De Ridder A, De Graeve D. Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach. Pharmacoeconomics. 2009;27(1):69–80.

    Article  PubMed  Google Scholar 

  16. Edwards SJ, Smith CJ. Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials. Clin Ther. 2009;31(Pt 1):1345–59.

    Article  CAS  PubMed  Google Scholar 

  17. Fleischhacker WW. Second-generation antipsychotic long-acting injections: systematic review. Br J Psychiatry Suppl. 2009;52:S29–36.

    Article  PubMed  Google Scholar 

  18. Fleischhacker WW, McQuade RD, Marcus RN, Archibald D, Swanink R, Carson WH. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry. 2009;65(6):510–7.

    Article  CAS  PubMed  Google Scholar 

  19. Haro JM, Novick D, Suarez D, Roca M. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study. J Psychiatr Res. 2009;43(3):265–73.

    Article  PubMed  Google Scholar 

  20. Hatta K, Sato K, Hamakawa H, Takebayashi H, Kimura N, Ochi S, et al. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia. Schizophr Res. 2009;113(1):49–55.

    Article  PubMed  Google Scholar 

  21. Hempel RJ, Tulen JH, van Beveren NJ, Roder CH, Hengeveld MW. Cardiovascular variability during treatment with haloperidol, olanzapine or risperidone in recent-onset schizophrenia. J Psychopharmacol. 2009;23(6):697–707.

    Article  CAS  PubMed  Google Scholar 

  22. Hrdlicka M, Zedkova I, Blatny M, Urbanek T. Weight gain associated with atypical and typical antipsychotics during treatment of adolescent schizophrenic psychoses: a retrospective study. Neuro Endocrinol Lett. 2009;30(2):256–61.

    CAS  PubMed  Google Scholar 

  23. Ingole S, Belorkar NR, Waradkar P, Shrivastava M. Comparison of effects of olanzapine and risperidone on body mass index and blood sugar level in schizophrenic patients. Indian J Physiol Pharmacol. 2009;53(1):47–54.

    CAS  PubMed  Google Scholar 

  24. Janicak PG, Glick ID, Marder SR, Crandall DT, McQuade RD, Marcus RN, et al. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. J Clin Psychiatry. 2009;70(1):25–35.

    Article  CAS  PubMed  Google Scholar 

  25. Jarbrink K, Kreif N, Benedict A, Locklear J. Quality of life and drug costs associated with switching antipsychotic medication to once-daily extended release quetiapine fumarate in patients with schizophrenia. Curr Med Res Opin. 2009;25(3):709–16.

    Article  PubMed  Google Scholar 

  26. Kane JM, Osuntokun O, Kryzhanovskaya LA, Xu W, Stauffer VL, Watson SB, et al. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J Clin Psychiatry. 2009;70(4):572–81.

    Article  CAS  PubMed  Google Scholar 

  27. Karagianis J, Williams R, Davis L, Procyshyn R, Monga N, Hanley J, et al. Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia. Curr Med Res Opin. 2009;25(9):2121–32.

    Article  PubMed  Google Scholar 

  28. Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Bhoopathi PS, Kissling W, et al. Ziprasidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009;(4):CD006627.

  29. Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Schmidt F, Lewis R, et al. Sertindole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009;(2):CD006752.

  30. Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, El-Sayeh HG, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2009;(4):CD006569.

  31. Konarzewska B, Wolczynski S, Szulc A, Galinska B, Poplawska R, Waszkiewicz N. Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia. Psychoneuroendocrinology. 2009;34(1):129–39.

    Article  CAS  PubMed  Google Scholar 

  32. Krakowski M, Czobor P, Citrome L. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. Schizophr Res. 2009;110(1–3):95–102.

    Article  PubMed  Google Scholar 

  33. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41.

    Article  CAS  PubMed  Google Scholar 

  34. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166(2):152–63.

    Article  PubMed  Google Scholar 

  35. Lindner LM, Marasciulo AC, Farias MR, Grohs GE. Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System. Rev Saude Publica. 2009;43(Suppl 1):62–9.

    PubMed  Google Scholar 

  36. Lublin H, Haug HJ, Koponen H, Sigmundsson T, Kolb SA. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial. World J Biol Psychiatry. 2009;10(4 Pt 3):710–8.

    Article  PubMed  Google Scholar 

  37. Mizrahi R, Mamo D, Rusjan P, Graff A, Houle S, Kapur S. The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics. Int J Neuropsychopharmacol. 2009;12(5):715–21.

    Article  CAS  PubMed  Google Scholar 

  38. Mohamed S, Rosenheck R, Harpaz-Rotem I, Leslie D, Sernyak MJ. Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia. Psychiatr Q. 2009;80(4):241–9.

    Article  PubMed  Google Scholar 

  39. Newcomer JW, Ratner RE, Eriksson JW, Emsley R, Meulien D, Miller F, et al. A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone. J Clin Psychiatry. 2009;70(4):487–99.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  40. Novick D, Haro JM, Perrin E, Suarez D, Texeira JM. Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Eur Neuropsychopharmacol. 2009;19(8):542–50.

    Article  CAS  PubMed  Google Scholar 

  41. Olivares JM, Rodriguez-Morales A, Diels J, Povey M, Jacobs A, Zhao Z, et al. Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR). Eur Psychiatry. 2009;24(5):287–96.

    Article  CAS  PubMed  Google Scholar 

  42. Ozbilen M, Adams CE. Systematic overview of Cochrane reviews for anticholinergic effects of antipsychotic drugs. J Clin Psychopharmacol. 2009;29(2):141–6.

    Article  CAS  PubMed  Google Scholar 

  43. Parsons B, Allison DB, Loebel A, Williams K, Giller E, Romano S, et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res. 2009;110(1–3):103–10.

    Article  PubMed  Google Scholar 

  44. Penn DL, Keefe RS, Davis SM, Meyer PS, Perkins DO, Losardo D, et al. The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophr Res. 2009;115(1):17–23.

    Article  PubMed Central  PubMed  Google Scholar 

  45. Peuskens J, Gillain B, De Graeve D, Van Vleymen B, Albert A. Belgian Schizophrenia Outcome Survey: results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol. Eur Psychiatry. 2009;24(3):154–63.

    Article  CAS  PubMed  Google Scholar 

  46. Ried LD, Brumback B, Bengtson MA, Garman PM, Hsu C, McConkey JR. Glucose dysregulation among veterans living with schizophrenia-related disorders after switching second-generation antipsychotics. J Am Pharm Assoc (2003). 2009;49(2):223–31.

    Article  Google Scholar 

  47. Rosenheck RA, Davis S, Covell N, Essock S, Swartz M, Stroup S, et al. Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. Schizophr Res. 2009;107(1):22–9.

    Article  PubMed  Google Scholar 

  48. Ryckmans V, Kahn JP, Modell S, Werner C, McQuade RD, Kerselaers W, et al. Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study. Pharmacopsychiatry. 2009;42(3):114–21.

    Article  CAS  PubMed  Google Scholar 

  49. Shajahan P, Keith S, Majjiga C, Murphy J, MacRae A, Bashir M, et al. Comparing the effectiveness of aripiprazole and quetiapine in schizophrenia and related psychoses: a naturalistic, retrospective chart review study. J Clin Psychiatry. 2009;70(5):692–8.

    Article  CAS  PubMed  Google Scholar 

  50. Smith RC, Lindenmayer JP, Davis JM, Kelly E, Viviano TF, Cornwell J, et al. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study. J Clin Psychiatry. 2009;70(11):1501–13.

    Article  CAS  PubMed  Google Scholar 

  51. Stauffer V, Ascher-Svanum H, Liu L, Ball T, Conley R. Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials. BMC Psychiatry. 2009;9:13.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  52. Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RS, et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res. 2009;107(1):1–12.

    Article  PubMed Central  PubMed  Google Scholar 

  53. Su KP, Chang HC, Tsai SJ, Yen FC, Tang CH. Relapse and long-acting injectable risperidone: a 1-year mirror image study with a national claims database in Taiwan. Value Health. 2009;12(Suppl 3):S118–21.

    Article  PubMed  Google Scholar 

  54. Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620–7.

    Article  PubMed  Google Scholar 

  55. Tschoner A, Engl J, Rettenbacher M, Edlinger M, Kaser S, Tatarczyk T, et al. Effects of six second generation antipsychotics on body weight and metabolism—risk assessment and results from a prospective study. Pharmacopsychiatry. 2009;42(1):29–34.

    Article  CAS  PubMed  Google Scholar 

  56. Woo YS, Kim W, Chae JH, Yoon BH, Bahk WM. Blood pressure changes during clozapine or olanzapine treatment in Korean schizophrenic patients. World J Biol Psychiatry. 2009;10(4 Pt 2):420–5.

    Article  PubMed  Google Scholar 

  57. Yang L, Li M, Tao LB, Zhang M, Nicholl MD, Dong P. Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China. Value Health. 2009;12(Suppl 3):S66–9.

    Article  PubMed  Google Scholar 

  58. Yasui-Furukori N, Sato Y, Furukori H, Saito M, Nakagami T, Kaneko S. Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine. J Clin Psychiatry. 2009;70(1):95–100.

    Article  CAS  PubMed  Google Scholar 

  59. Yu AP, Atanasov P, Ben-Hamadi R, Birnbaum H, Stensland MD, Philips G. Resource utilization and costs of schizophrenia patients treated with olanzapine versus quetiapine in a Medicaid population. Value Health. 2009;12(5):708–15.

    Article  PubMed  Google Scholar 

  60. Yu AP, Ben-Hamadi R, Birnbaum HG, Atanasov P, Stensland MD, Philips G. Comparing the treatment patterns of patients with schizophrenia treated with olanzapine and quetiapine in the Pennsylvania Medicaid population. Curr Med Res Opin. 2009;25(3):755–64.

    Article  CAS  PubMed  Google Scholar 

  61. Ardizzone I, Nardecchia F, Marconi A, Carratelli TI, Ferrara M. Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials. Psychopharmacol Bull. 2010;43(2):45–66.

    PubMed  Google Scholar 

  62. Asenjo Lobos C, Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;(11):CD006633.

  63. Bhowmick S, Hazra A, Ghosh M. Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial. Aust N Z J Psychiatry. 2010;44(3):237–42.

    Article  PubMed  Google Scholar 

  64. Bushe C, Sniadecki J, Bradley AJ, Poole Hoffmann V. Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia. J Psychopharmacol. 2010;24(7):1001–9.

    Article  CAS  PubMed  Google Scholar 

  65. Carswell C, Wheeler A, Vanderpyl J, Robinson E. Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis. Clin Drug Investig. 2010;30(11):777–87.

    Article  CAS  PubMed  Google Scholar 

  66. Chan HY, Chang CJ, Chiang SC, Chen JJ, Chen CH, Sun HJ, et al. A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced acute dystonia or parkinsonism. J Psychopharmacol. 2010;24(1):91–8.

    Article  CAS  PubMed  Google Scholar 

  67. Chan HY, Chiang SC, Chang CJ, Gau SS, Chen JJ, Chen CH, et al. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia. J Clin Psychiatry. 2010;71(9):1226–33.

    Article  CAS  PubMed  Google Scholar 

  68. Crocq MA, Naber D, Lader MH, Thibaut F, Drici M, Everitt B, et al. Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone. Eur Neuropsychopharmacol. 2010;20(12):829–38.

    Article  CAS  PubMed  Google Scholar 

  69. Docherty JP, Baker RA, Eudicone J, Mathew S, Marcus RN, McQuade RD, et al. Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia. Schizophr Res. 2010;120(1–3):199–203.

    Article  CAS  PubMed  Google Scholar 

  70. Findling RL, Johnson JL, McClellan J, Frazier JA, Vitiello B, Hamer RM, et al. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry. 2010;49(6):583–94 (quiz 632).

    PubMed Central  PubMed  Google Scholar 

  71. Gaebel W, Schreiner A, Bergmans P, de Arce R, Rouillon F, Cordes J, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology. 2010;35(12):2367–77.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  72. Gafoor R, Landau S, Craig TK, Elanjithara T, Power P, McGuire P. Esquire trial: efficacy and adverse effects of quetiapine versus risperidone in first-episode schizophrenia. J Clin Psychopharmacol. 2010;30(5):600–6.

    Article  CAS  PubMed  Google Scholar 

  73. Grootens KP, van Veelen NM, Sitskoorn MM, Sabbe BG, Peuskens J, Buitelaar JK, et al. Effects on cognitive functioning after olanzapine-ziprasidone crossover in recent-onset schizophrenia. Eur Neuropsychopharmacol. 2010;20(12):907–12.

    Article  CAS  PubMed  Google Scholar 

  74. Hensen M, Heeg B, Lothgren M, van Hout B. Cost effectiveness of long-acting risperidone in Sweden. Appl Health Econ Health Policy. 2010;8(5):327–41.

    Article  PubMed  Google Scholar 

  75. Jones MP, Nicholl D, Trakas K. Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia. Int J Clin Pharmacol Ther. 2010;48(6):383–99.

    Article  CAS  PubMed  Google Scholar 

  76. Kane JM, Barnes TR, Correll CU, Sachs G, Buckley P, Eudicone J, et al. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. J Psychopharmacol. 2010;24(7):1019–29.

    Article  CAS  PubMed  Google Scholar 

  77. Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2010;30(2):106–15.

    Article  CAS  PubMed  Google Scholar 

  78. Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010;167(2):181–9.

    Article  PubMed  Google Scholar 

  79. Kelly DL, McMahon RP, Liu F, Love RC, Wehring HJ, Shim JC, et al. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry. 2010;71(3):304–11.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  80. Kim SH, Han DH, Joo SY, Min KJ. The effect of dopamine partial agonists on the nicotine dependency in patients with schizophrenia. Hum Psychopharmacol. 2010;25(2):187–90.

    Article  CAS  PubMed  Google Scholar 

  81. Kim SW, Shin IS, Kim JM, Bae KY, Yang SJ, Yoon JS. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia. Clin Neuropharmacol. 2010;33(3):121–5.

    Article  CAS  PubMed  Google Scholar 

  82. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;(3):CD006654.

  83. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Kissling W, et al. Zotepine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;(1):CD006628.

  84. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Silveira da Mota Neto JI, et al. Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;(1):CD006624.

  85. Komossa K, Rummel-Kluge C, Schmid F, Hunger H, Schwarz S, Srisurapanont M, et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010;(1):CD006625.

  86. Liew A, Verma S, Lye Yin P, Edimansyah A, Subramaniam M, Vaingankar J, et al. Comparing effectiveness of risperidone with first-generation antipsychotic medications in patients with schizophrenia-spectrum disorders. J Psychopharmacol. 2010;24(7):973–80.

    Article  CAS  PubMed  Google Scholar 

  87. McIntyre RS, Cragin L, Sorensen S, Naci H, Baker T, Roussy JP. Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis. J Eval Clin Pract. 2010;16(4):744–55.

    Article  PubMed  Google Scholar 

  88. Melnik T, Soares BG, Puga ME, Atallah AN. Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews. Sao Paulo Med J. 2010;128(3):141–66.

    Article  PubMed  Google Scholar 

  89. Mukundan A, Faulkner G, Cohn T, Remington G. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems. Cochrane Database Syst Rev. 2010;(12):CD006629.

  90. Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients. Neuropsychopharmacology. 2010;35(9):1997–2004.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  91. Novick D, Haro JM, Bertsch J, Haddad PM. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. J Clin Psychopharmacol. 2010;30(5):531–40.

    Article  PubMed  Google Scholar 

  92. Ortega I, Perez-Ruixo JJ, Stuyckens K, Piotrovsky V, Vermeulen A. Modeling the effectiveness of paliperidone ER and olanzapine in schizophrenia: meta-analysis of 3 randomized, controlled clinical trials. J Clin Pharmacol. 2010;50(3):293–310.

    Article  CAS  PubMed  Google Scholar 

  93. Ozeki Y, Fujii K, Kurimoto N, Yamada N, Okawa M, Aoki T, et al. QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(2):401–5.

    Article  CAS  PubMed  Google Scholar 

  94. Riedel M, Schennach-Wolff R, Musil R, Dehning S, Cerovecki A, Opgen-Rhein M, et al. Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidone. Hum Psychopharmacol. 2010;25(2):116–25.

    Article  CAS  PubMed  Google Scholar 

  95. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123(2–3):225–33.

    Article  PubMed Central  PubMed  Google Scholar 

  96. Schoemaker J, Naber D, Vrijland P, Panagides J, Emsley R. Long-term assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry. 2010;43(4):138–46.

    Article  CAS  PubMed  Google Scholar 

  97. Thomas SH, Drici MD, Hall GC, Crocq MA, Everitt B, Lader MH, et al. Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP). Acta Psychiatr Scand. 2010;122(5):345–55.

    Article  CAS  PubMed  Google Scholar 

  98. Ulcickas Yood M, Delorenze G, Quesenberry CP Jr, Tsai AL, Phillips S, Willey VJ, et al. Epidemiologic study of aripiprazole use and the incidence of suicide events. Pharmacoepidemiol Drug Saf. 2010;19(11):1124–30.

    Article  PubMed  Google Scholar 

  99. van Veelen NM, Grootens KP, Peuskens J, Sabbe BG, Salden ME, Verkes RJ, et al. Short term neurocognitive effects of treatment with ziprasidone and olanzapine in recent onset schizophrenia. Schizophr Res. 2010;120(1–3):191–8.

    Article  PubMed  Google Scholar 

  100. Willis M, Svensson M, Lothgren M, Eriksson B, Berntsson A, Persson U. The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden. Eur J Health Econ. 2010;11(6):585–94.

    Article  PubMed  Google Scholar 

  101. Ascher-Svanum H, Stensland MD, Peng X, Faries DE, Stauffer VL, Osuntokun OO, et al. Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia. Curr Med Res Opin. 2011;27(1):115–22.

    Article  PubMed  Google Scholar 

  102. Chung AK, Chua SE. Effects on prolongation of Bazett’s corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis. J Psychopharmacol. 2011;25(5):646–66.

    PubMed  Google Scholar 

  103. Crabtree BL, Montgomery J. Iloperidone for the management of adults with schizophrenia. Clin Ther. 2011;33(3):330–45.

    Article  CAS  PubMed  Google Scholar 

  104. Ganguli R, Brar JS, Garbut R, Chang CC, Basu R. Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole. Clin Schizophr Relat Psychoses. 2011;5(2):75–9.

    Article  PubMed  Google Scholar 

  105. Girgis RR, Merrill DB, Vorel SR, Edward K, Kimberly P, You M, et al. Aripiprazole versus haloperidol treatment in early-stage schizophrenia. J Psychiatr Res. 2011;45(6):756–62.

    Article  PubMed Central  PubMed  Google Scholar 

  106. Glick ID, Correll CU, Altamura AC, Marder SR, Csernansky JG, Weiden PJ, et al. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. J Clin Psychiatry. 2011;72(12):1616–27.

    Article  CAS  PubMed  Google Scholar 

  107. Grootens KP, van Veelen NM, Peuskens J, Sabbe BG, Thys E, Buitelaar JK, et al. Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. Schizophr Bull. 2011;37(2):352–61.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  108. Guo X, Fang M, Zhai J, Wang B, Wang C, Hu B, et al. Effectiveness of maintenance treatments with atypical and typical antipsychotics in stable schizophrenia with early stage: 1-year naturalistic study. Psychopharmacology (Berl). 2011;216(4):475–84.

    Article  CAS  PubMed  Google Scholar 

  109. Guo X, Zhai J, Wei Q, Twamley EW, Jin H, Fang M, et al. Neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: a naturalistic 12-month follow-up study. Neurosci Lett. 2011;503(2):141–6.

    Article  CAS  PubMed  Google Scholar 

  110. Hardy TA, Henry RR, Forrester TD, Kryzhanovskaya LA, Campbell GM, Marks DM, et al. Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder. Diabetes Obes Metab. 2011;13(8):726–35.

    Article  CAS  PubMed  Google Scholar 

  111. Hatta K, Otachi T, Sudo Y, Hayakawa T, Ashizawa Y, Takebayashi H, et al. Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia. Schizophr Res. 2011;128(1–3):127–35.

    Article  PubMed  Google Scholar 

  112. Karayal ON, Glue P, Bachinsky M, Stewart M, Chappell P, Kolluri S, et al. Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder. J Psychiatr Pract. 2011;17(2):100–9.

    Article  PubMed  Google Scholar 

  113. Kasteng F, Eriksson J, Sennfalt K, Lindgren P. Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder. Acta Psychiatr Scand. 2011;124(3):214–25.

    Article  CAS  PubMed  Google Scholar 

  114. Kim K, Aas E. Cost-effectiveness analysis of olanzapine and risperidone in Norway. J Ment Health Policy Econ. 2011;14(3):125–35.

    CAS  PubMed  Google Scholar 

  115. King D, Knapp M, Thomas P, Razzouk D, Loze JY, Kan HJ, et al. Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study. Curr Med Res Opin. 2011;27(2):365–74.

    Article  CAS  PubMed  Google Scholar 

  116. Klemp M, Tvete IF, Skomedal T, Gaasemyr J, Natvig B, Aursnes I. A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo. J Clin Psychopharmacol. 2011;31(6):698–704.

    Article  CAS  PubMed  Google Scholar 

  117. Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, et al. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2011;(1):CD006626.

  118. Kreyenbuhl J, Slade EP, Medoff DR, Brown CH, Ehrenreich B, Afful J, et al. Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia. Schizophr Res. 2011;131(1–3):127–32.

    Article  PubMed  Google Scholar 

  119. Lee NY, Kim SH, Jung DC, Kim EY, Yu HY, Sung KH, et al. The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving a monotherapy with aripiprazole, olanzapine or risperidone. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(5):1273–8.

    Article  CAS  PubMed  Google Scholar 

  120. Lee SY, Park MH, Patkar AA, Pae CU. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(2):490–6.

    Article  CAS  PubMed  Google Scholar 

  121. Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries DE, Lawson AH. Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study. Schizophr Res. 2011;133(1–3):42–6.

    Article  PubMed  Google Scholar 

  122. Li H, Rui Q, Ning X, Xu H, Gu N. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(4):1002–8.

    Article  CAS  PubMed  Google Scholar 

  123. Liemburg E, Aleman A, Bous J, Hollander K, Knegtering H. An open randomized pilot trial on the differential effects of aripiprazole versus risperidone on anhedonia and subjective well-being. Pharmacopsychiatry. 2011;44(3):109–13.

    Article  CAS  PubMed  Google Scholar 

  124. Lindstrom E, Eberhard J, Fors BM, Hansen K, Sapin C. A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden. Nord J Psychiatry. 2011;65(6):403–13.

    Article  PubMed  Google Scholar 

  125. Liu-Seifert H, Ascher-Svanum H, Osuntokun O, Jen KY, Gomez JC. Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics. BMC Psychiatry. 2011;11:87.

    Article  PubMed Central  PubMed  Google Scholar 

  126. McDonnell DP, Kryzhanovskaya LA, Zhao F, Detke HC, Feldman PD. Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine. Hum Psychopharmacol. 2011;26(6):422–33.

    CAS  PubMed  Google Scholar 

  127. Melkersson K, Berinder K, Hulting AL. Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses. Neuro Endocrinol Lett. 2011;32(4):428–36.

    CAS  PubMed  Google Scholar 

  128. Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry. 2011;168(9):957–67.

    Article  PubMed  Google Scholar 

  129. Mihajlovic G, Jovanovic-Mihajlovic N, Radmanovic B, Radonjic K, Djukic-Dejanovic S, Jankovic S, et al. Quality of life of schizophrenic patients treated with haloperidol depot and injection preparation of long-lasting risperidone. Srp Arh Celok Lek. 2011;139(Suppl 1):36–40.

    Article  PubMed  Google Scholar 

  130. Pandina G, Lane R, Gopal S, Gassmann-Mayer C, Hough D, Remmerie B, et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):218–26.

    Article  CAS  PubMed  Google Scholar 

  131. Popovic I, Ravanic D, Popovic V, Vladejic S, Stanojevic A, Stojanovic M. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients. Psychiatr Danub. 2011;23(4):384–8.

    CAS  PubMed  Google Scholar 

  132. Potkin SG, Ogasa M, Cucchiaro J, Loebel A. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder. Schizophr Res. 2011;132(2–3):101–7.

    Article  PubMed  Google Scholar 

  133. Raposo NR, Ferreira AS, Gattaz WF. Body mass index increase, serum leptin, adiponectin, neuropeptide Y and lipid levels during treatment with olanzapine and haloperidol. Pharmacopsychiatry. 2011;44(5):169–72.

    Article  CAS  PubMed  Google Scholar 

  134. Strom BL, Eng SM, Faich G, Reynolds RF, D’Agostino RB, Ruskin J, et al. Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Am J Psychiatry. 2011;168(2):193–201.

    Article  PubMed  Google Scholar 

  135. Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry. 2011;168(9):947–56.

    Article  PubMed Central  PubMed  Google Scholar 

  136. Suzuki H, Gen K, Inoue Y. An unblinded comparison of the clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(1):161–8.

    Article  CAS  PubMed  Google Scholar 

  137. Suzuki T, Remington G, Uchida H, Rajji TK, Graff-Guerrero A, Mamo DC. Management of schizophrenia in late life with antipsychotic medications: a qualitative review. Drugs Aging. 2011;28(12):961–80.

    Article  CAS  PubMed  Google Scholar 

  138. Turkoz I, Bossie CA, Lindenmayer JP, Schooler N, Canuso CM. Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis. BMC Psychiatry. 2011;11:21.

    Article  PubMed Central  PubMed  Google Scholar 

  139. Volavka J, Czobor P, Derks EM, Bitter I, Libiger J, Kahn RS, et al. Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). J Clin Psychiatry. 2011;72(7):955–61.

    Article  PubMed  Google Scholar 

  140. Werneck AP, Hallak JC, Nakano E, Elkis H. Time to rehospitalization in patients with schizophrenia discharged on first generation antipsychotics, non-clozapine second generation antipsychotics, or clozapine. Psychiatry Res. 2011;188(3):315–9.

    Article  CAS  PubMed  Google Scholar 

  141. Wichniak A, Skowerska A, Chojnacka-Wojtowicz J, Taflinski T, Wierzbicka A, Jernajczyk W, et al. Actigraphic monitoring of activity and rest in schizophrenic patients treated with olanzapine or risperidone. J Psychiatr Res. 2011;45(10):1381–6.

    Article  PubMed  Google Scholar 

  142. Yang FD, Wang XQ, Liu XP, Zhao KX, Fu WH, Hao XR, et al. Sex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychotics. Psychopharmacology (Berl). 2011;216(1):9–16.

    Article  CAS  PubMed  Google Scholar 

  143. Zedkova I, Dudova I, Urbanek T, Hrdlicka M. Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses. Neuro Endocrinol Lett. 2011;32(5):667–70.

    CAS  PubMed  Google Scholar 

  144. Ascher-Svanum H, Furiak NM, Lawson AH, Klein TM, Smolen LJ, Conley RR, et al. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States. J Med Econ. 2012;15(3):531–47.

    Article  PubMed  Google Scholar 

  145. Ben Amor L. Antipsychotics in pediatric and adolescent patients: a review of comparative safety data. J Affect Disord. 2012;138 Suppl:S22–30.

  146. Buchanan RW, Panagides J, Zhao J, Phiri P, den Hollander W, Ha X, et al. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol. 2012;32(1):36–45.

    Article  CAS  PubMed  Google Scholar 

  147. Bushe CJ, Slooff CJ, Haddad PM, Karagianis JL. Weight change from 3-year observational data: findings from the worldwide schizophrenia outpatient health outcomes database. J Clin Psychiatry. 2012;73(6):e749–55.

    Article  PubMed  Google Scholar 

  148. Chang HC, Tang CH, Huang ST, McCrone P, Su KP. A cost-consequence analysis of long-acting injectable risperidone in schizophrenia: a one-year mirror-image study with national claim-based database in Taiwan. J Psychiatr Res. 2012;46(6):751–6.

    Article  PubMed  Google Scholar 

  149. Chen JJ, Chan HY, Chen CH, Gau SS, Hwu HG. Risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics. Pharmacopsychiatry. 2012;45(2):64–71.

    Article  CAS  PubMed  Google Scholar 

  150. Chen Y, Bobo WV, Watts K, Jayathilake K, Tang T, Meltzer HY. Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study. J Psychopharmacol. 2012;26(9):1201–10.

    Article  PubMed  CAS  Google Scholar 

  151. Citrome L. A systematic review of meta-analyses of the efficacy of oral atypical antipsychotics for the treatment of adult patients with schizophrenia. Expert Opin Pharmacother. 2012;13(11):1545–73.

    Article  CAS  PubMed  Google Scholar 

  152. Citrome L, Cucchiaro J, Sarma K, Phillips D, Silva R, Tsuchiya S, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol. 2012;27(3):165–76.

    Article  PubMed  Google Scholar 

  153. Covell NH, McEvoy JP, Schooler NR, Stroup TS, Jackson CT, Rojas IA, et al. Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. J Clin Psychiatry. 2012;73(5):669–75.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  154. de Arce Cordon R, Eding E, Marques-Teixeira J, Milanova V, Rancans E, Schreiner A. Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Eur Arch Psychiatry Clin Neurosci. 2012;262(2):139–49.

    Article  PubMed  Google Scholar 

  155. De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs. 2012;26(9):733–59.

    Article  PubMed  Google Scholar 

  156. Duncan EJ, Woolson SL, Hamer RM. Treatment compliance in veterans administration schizophrenia spectrum patients treated with risperidone long-acting injectable. Int Clin Psychopharmacol. 2012;27(5):283–90.

    Article  PubMed  Google Scholar 

  157. Feng S, Melkersson K. Metabolic parameters and long-term antipsychotic treatment: a comparison between patients treated with clozapine or olanzapine. Neuro Endocrinol Lett. 2012;33(5):493–8.

    CAS  PubMed  Google Scholar 

  158. Graham CN, Mauskopf JA, Lawson AH, Ascher-Svanum H, Bruhn D. Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia. Value Health. 2012;15(1):55–64.

    Article  PubMed  Google Scholar 

  159. Grimaldi-Bensouda L, Rouillon F, Astruc B, Rossignol M, Benichou J, Falissard B, et al. Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophr Res. 2012;134(2–3):187–94.

    Article  PubMed  Google Scholar 

  160. Guo X, Zhang Z, Zhai J, Fang M, Hu M, Wu R, et al. Effects of antipsychotic medications on quality of life and psychosocial functioning in patients with early-stage schizophrenia: 1-year follow-up naturalistic study. Compr Psychiatry. 2012;53(7):1006–12.

    Article  PubMed  Google Scholar 

  161. Hartling L, Abou-Setta AM, Dursun S, Mousavi SS, Pasichnyk D, Newton AS. Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis. Ann Intern Med. 2012;157(7):498–511.

    Article  PubMed  Google Scholar 

  162. Hong J, Novick D, Brugnoli R, Karagianis J, Dossenbach M, Haro JM. Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study. BMC Psychiatry. 2012;12:218.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  163. Hori H, Yoshimura R, Katsuki A, Hayashi K, Ikenouchi-Sugita A, Umene-Nakano W, et al. The cognitive profile of aripiprazole differs from that of other atypical antipsychotics in schizophrenia patients. J Psychiatr Res. 2012;46(6):757–61.

    Article  PubMed  Google Scholar 

  164. Kaushal J, Bhutani G, Gupta R. Comparison of fasting blood sugar and serum lipid profile changes after treatment with atypical antipsychotics olanzapine and risperidone. Singapore Med J. 2012;53(7):488–92.

    PubMed  Google Scholar 

  165. Kilian R, Steinert T, Schepp W, Weiser P, Jaeger S, Pfiffner C, et al. Effectiveness of antipsychotic maintenance therapy with quetiapine in comparison with risperidone and olanzapine in routine schizophrenia treatment: results of a prospective observational trial. Eur Arch Psychiatry Clin Neurosci. 2012;262(7):589–98.

    Article  PubMed  Google Scholar 

  166. Kim SW, Chung YC, Lee YH, Lee JH, Kim SY, Bae KY, et al. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial. Int Clin Psychopharmacol. 2012;27(5):267–74.

    Article  PubMed  Google Scholar 

  167. Kraemer S, Chartier F, Augendre-Ferrante B, Psarra V, D’Yachkova Y, Beselin A, et al. Effectiveness of two formulations of oral olanzapine in patients with schizophrenia or bipolar disorder in a natural setting: results from a 1-year European observational study. Hum Psychopharmacol. 2012;27(3):284–94.

    Article  CAS  PubMed  Google Scholar 

  168. Kucharska-Pietura K, Tylec A, Czernikiewicz A, Mortimer A. Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs. Med Sci Monit. 2012;18(1):CR44–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  169. Li Y, Li H, Liu Y, Yan X, Yue Y, Qian M. Comparison of quetiapine and risperidone in Chinese Han patients with schizophrenia: results of a single-blind, randomized study. Curr Med Res Opin. 2012;28(10):1725–32.

    Article  CAS  PubMed  Google Scholar 

  170. Li YM, Zhao JP, Ou JJ, Wu RR. Efficacy and tolerability of ziprasidone vs. olanzapine in naive first-episode schizophrenia: a 6-week, randomized, open-label, flexible-dose study. Pharmacopsychiatry. 2012;45(5):177–81.

    CAS  PubMed  Google Scholar 

  171. Mehnert A, Nicholl D, Pudas H, Martin M, McGuire A. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. J Med Econ. 2012;15(5):844–61.

    Article  PubMed  Google Scholar 

  172. Nordon C, Rouillon F, Barry C, Gasquet I, Falissard B. Determinants of treatment satisfaction of schizophrenia patients: results from the ESPASS study. Schizophr Res. 2012;139(1–3):211–7.

    Article  PubMed  Google Scholar 

  173. Nussbaum AM, Stroup TS. Paliperidone palmitate for schizophrenia. Cochrane Database Syst Rev. 2012;(6):CD008296.

  174. Olfson M, Gerhard T, Huang C, Lieberman JA, Bobo WV, Crystal S. Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia. Schizophr Bull. 2012;38(4):845–53.

    Article  PubMed Central  PubMed  Google Scholar 

  175. Rosa F, Schreiner A, Thomas P, Sherif T. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable. Clin Drug Investig. 2012;32(4):267–79.

    Article  CAS  PubMed  Google Scholar 

  176. Rybakowski JK, Vansteelandt K, Szafranski T, Thys E, Jarema M, Wolfgang Fleischhacker W, et al. Treatment of depression in first episode of schizophrenia: results from EUFEST. Eur Neuropsychopharmacol. 2012;22(12):875–82.

    Article  CAS  PubMed  Google Scholar 

  177. San L, Arranz B, Perez V, Safont G, Corripio I, Ramirez N, et al. One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis. Psychiatry Res. 2012;200(2–3):693–701.

    Article  CAS  PubMed  Google Scholar 

  178. Sato G, Yoshimura S, Yamashita H, Okamoto Y, Yamawaki S. The neurocognitive effects of aripiprazole compared with risperidone in the treatment of schizophrenia. Hiroshima J Med Sci. 2012;61(4):75–83.

    CAS  PubMed  Google Scholar 

  179. Scheltema Beduin AA, Swets M, Machielsen M, Korver N. Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients. J Clin Psychiatry. 2012;73(11):1395–402.

    Article  PubMed  CAS  Google Scholar 

  180. Schoemaker J, Stet L, Vrijland P, Naber D, Panagides J, Emsley R. Long-term efficacy and safety of asenapine or olanzapine in patients with schizophrenia or schizoaffective disorder: an extension study. Pharmacopsychiatry. 2012;45(5):196–203.

    CAS  PubMed  Google Scholar 

  181. Schreiner A, Niehaus D, Shuriquie NA, Aadamsoo K, Korcsog P, Salinas R, et al. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial. J Clin Psychopharmacol. 2012;32(4):449–57.

    Article  CAS  PubMed  Google Scholar 

  182. Schuster JP, Raucher-Chene D, Lemogne C, Rouillon F, Gasquet I, Leguay D, et al. Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia. J Clin Psychopharmacol. 2012;32(5):672–7.

    Article  CAS  PubMed  Google Scholar 

  183. Seida JC, Schouten JR, Boylan K, Newton AS, Mousavi SS, Beaith A, et al. Antipsychotics for children and young adults: a comparative effectiveness review. Pediatrics. 2012;129(3):e771–84.

    Article  PubMed  Google Scholar 

  184. Suzuki H, Gen K. The influence of switching from haloperidol decanoate depot to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia. Hum Psychopharmacol. 2012;27(5):470–5.

    Article  CAS  PubMed  Google Scholar 

  185. Szegedi A, Verweij P, van Duijnhoven W, Mackle M, Cazorla P, Fennema H. Meta-analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics. J Clin Psychiatry. 2012;73(12):1533–40.

    Article  CAS  PubMed  Google Scholar 

  186. Treur M, Baca E, Bobes J, Canas F, Salvador L, Gonzalez B, et al. The cost-effectiveness of paliperidone extended release in Spain. J Med Econ. 2012;15(Suppl 1):26–34.

    Article  PubMed  Google Scholar 

  187. Wampers M, Hanssens L, van Winkel R, Heald A, Collette J, Peuskens J, et al. Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study. Eur Neuropsychopharmacol. 2012;22(1):17–26.

    Article  CAS  PubMed  Google Scholar 

  188. Wasserman JI, Barry RJ, Bradford L, Delva NJ, Beninger RJ. Probabilistic classification and gambling in patients with schizophrenia receiving medication: comparison of risperidone, olanzapine, clozapine and typical antipsychotics. Psychopharmacology (Berl). 2012;222(1):173–83.

    Article  CAS  PubMed  Google Scholar 

  189. Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa-McMillan A. Maintenance treatment with long-acting injectable risperidone in first-episode schizophrenia: a randomized effectiveness study. J Clin Psychiatry. 2012;73(9):1224–33.

    Article  CAS  PubMed  Google Scholar 

  190. Wu XL, Wang JH, Hu SH, Tao J. Serum prolactin levels and the acute-phase efficacy in drug-naive schizophrenia treated with ziprasidone and olanzapine (translated version). East Asian Arch Psychiatry. 2012;22(1):7–11.

    CAS  PubMed  Google Scholar 

  191. Achilla E, McCrone P. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: a systematic review of economic evaluations. Appl Health Econ Health Policy. 2013;11(2):95–106.

    Article  PubMed  Google Scholar 

  192. Bushe CJ, Slooff CJ, Haddad PM, Karagianis JL. Weight change by baseline BMI from three-year observational data: findings from the Worldwide Schizophrenia Outpatient Health Outcomes Database. J Psychopharmacol. 2013;27(4):358–65.

    Article  PubMed  Google Scholar 

  193. Chaves KM, Serrano-Blanco A, Ribeiro SB, Soares LA, Guerra GC, do Socorro Costa Feitosa Alves M, et al. Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia. Psychiatr Q. 2013;84(1):125–35.

    Article  PubMed  Google Scholar 

  194. Crespo-Facorro B, Perez-Iglesias R, Mata I, Ortiz-Garcia de la Foz V, Martinez-Garcia O, Valdizan EM, et al. Aripiprazole, ziprasidone, and quetiapine in the treatment of first-episode nonaffective psychosis: results of a 6-week, randomized, flexible-dose, open-label comparison. J Clin Psychopharmacol. 2013;33(2):215–20.

    Article  CAS  PubMed  Google Scholar 

  195. Jin H, Shih PA, Golshan S, Mudaliar S, Henry R, Glorioso DK, et al. Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization. J Clin Psychiatry. 2013;74(1):10–8.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  196. Jindal KC, Singh GP, Munjal V. Aripiprazole versus olanzapine in the treatment of schizophrenia: a clinical study from India. Int J Psychiatry Clin Pract. 2013;17(1):21–9.

    Article  CAS  PubMed  Google Scholar 

  197. Khanna P, Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, El-Sayeh HG, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2013;(2):CD006569.

  198. Kuo CJ, Yang SY, Liao YT, Chen WJ, Lee WC, Shau WY, et al. Second-generation antipsychotic medications and risk of pneumonia in schizophrenia. Schizophr Bull. 2013;39(3):648–57.

    Article  PubMed Central  PubMed  Google Scholar 

  199. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–62.

    Article  CAS  PubMed  Google Scholar 

  200. Loebel A, Cucchiaro J, Sarma K, Xu L, Hsu C, Kalali AH, et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013;145(1–3):101–9.

    Article  PubMed  Google Scholar 

  201. Manchanda R, Chue P, Malla A, Tibbo P, Roy MA, Williams R, et al. Long-acting injectable antipsychotics: evidence of effectiveness and use. Can J Psychiatry. 2013;58(5 Suppl 1):5S–13S.

    PubMed  Google Scholar 

  202. McEvoy JP, Citrome L, Hernandez D, Cucchiaro J, Hsu J, Pikalov A, et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. J Clin Psychiatry. 2013;74(2):170–9.

    Article  CAS  PubMed  Google Scholar 

  203. Ou JJ, Xu Y, Chen HH, Fan X, Gao K, Wang J, et al. Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia. Psychopharmacology (Berl). 2013;225(3):627–35.

    Article  CAS  PubMed  Google Scholar 

  204. Souza JS, Kayo M, Tassell I, Martins CB, Elkis H. Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses. CNS Spectr. 2013;18(2):82–9.

    Article  PubMed  Google Scholar 

  205. Suzuki Y, Sugai T, Fukui N, Watanabe J, Ono S, Tsuneyama N, et al. Differences in plasma prolactin levels in patients with schizophrenia treated on monotherapy with five second-generation antipsychotics. Schizophr Res. 2013;145(1–3):116–9.

    Article  PubMed  Google Scholar 

  206. Oxford Centre for Evidence-Based Medicine UoO. Level of evidence. 2009. Available at: http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/. Accessed 10 Dec 2013.

Download references

Acknowledgments

Bruce Wong and Gregory Kruse undertook the independent literature assessments and initial writing of the manuscript. Marie-Hélène Lafeuille, Patrick Lefebvre, and Mei Sheng Duh developed the primary research concepts, the methodologic framework, and reviewed and contributed to the manuscript revision. John Fastenau provided overall research oversight and expert input into data interpretation and contributed to the manuscript revision.

Conflict of interest

Marie-Hélène Lafeuille, Patrick Lefebvre, and Mei Sheng Duh are employees of Analysis Group, Inc., a consulting company that has received research grants from Janssen Scientific Affairs, LLC. John M. Fastenau is an employee of Janssen Scientific Affairs, LLC. Gregory Kruse and Bruce J.O. Wong have received research funding from Janssen Scientific Affairs, LLC.

Financial support

Financial support for this study was provided by Janssen Scientific Affairs, LLC.

Author information

Authors and Affiliations

  1. The Wharton School, University of Pennsylvania, Philadelphia, PA, USA

    Gregory Kruse

  2. Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA

    Bruce J. O. Wong

  3. Analysis Group, Inc., Tenth Floor, 111 Huntington Avenue, Boston, MA, 02199, USA

    Mei Sheng Duh

  4. Groupe d’analyse, Ltée, Montréal, QC, Canada

    Patrick Lefebvre & Marie-Hélène Lafeuille

  5. Janssen Scientific Affairs, LLC, Titusville, NJ, USA

    John M. Fastenau

Authors
  1. Gregory Kruse
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bruce J. O. Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mei Sheng Duh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Patrick Lefebvre
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marie-Hélène Lafeuille
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. John M. Fastenau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mei Sheng Duh.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 644 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kruse, G., Wong, B.J.O., Duh, M.S. et al. Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment. PharmacoEconomics 33, 1049–1067 (2015). https://doi.org/10.1007/s40273-015-0285-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40273-015-0285-8

Keywords

Search

Navigation